Clinical Trials Browser

Phase 3 × Neuroendocrine Tumors × Clear all

NCT00569127 2026-05-26

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

Neuroendocrine Tumors

NCT06881992 2026-05-18

Tumor HI

Phase 3 Recruiting

EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT05918302 2026-05-12

LEVEL

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07087054 2026-04-30

CAREFNDR

Phase 3 Recruiting

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT03049189 2026-04-06

COMPETE

Phase 3 Active not recruiting

324 enrolled 15 charts

Neuroendocrine Tumors

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04810091 2026-03-09

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Phase 3 Active not recruiting

79 enrolled 24 charts

Neuroendocrine Tumors

NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

Phase 3 Recruiting

CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT07185672 2025-09-22

PReCedeNT

Phase 3 Recruiting

Neuroendocrine Tumors

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05387603 2025-09-10

START-NET

Phase 3 Recruiting

Neuroendocrine Tumors

NCT05459844 2025-09-05

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Phase 3 Active not recruiting

Neuroendocrine Tumors

NCT06878664 2025-09-02

RIALTO

Phase 3 Recruiting

Neuroendocrine Tumors

NCT02840149 2025-05-15

SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

Phase 3 Completed

Neuroendocrine Tumors

NCT02246127 2025-05-11

SEQTOR

Phase 3 Completed

141 enrolled 27 charts

Neuroendocrine Tumors

NCT04847505 2024-07-18

68Ga-DOTA-TATE PET/CT Imaging in NETs

Phase 3 Recruiting

Neuroendocrine Tumors

NCT03136328 2023-05-09

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

Phase 3 Completed

11 enrolled 5 charts

Neuroendocrine Tumors

NCT02588170 2023-03-30

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Phase 3 Completed

Neuroendocrine Tumors

NCT02589821 2023-03-30

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

Phase 3 Completed

Neuroendocrine Tumors

NCT03673943 2022-12-22

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Phase 3 Completed

63 enrolled 8 charts

Neuroendocrine Tumors

NCT01842165 2022-11-10

LUMEN

Phase 3 Completed

Neuroendocrine Tumors

NCT00774930 2022-10-14

ELECT

Phase 3 Completed

115 enrolled 17 charts

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT00842348 2022-10-12

NET729

Phase 3 Completed

89 enrolled 9 charts

Neuroendocrine Tumors

NCT01578239 2022-04-04

NETTER-1

Phase 3 Completed

231 enrolled 16 charts 2 FDA

Neuroendocrine Tumors

NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

Phase 3 Completed

CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

NCT01524783 2021-08-05

RADIANT-4

Phase 3 Completed

302 enrolled 16 charts

Neuroendocrine Tumors

NCT00171873 2020-03-26

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Phase 3 Completed

85 enrolled 6 charts

Disease, Neoplasms, Neuroendocrine Tumors

NCT00037869 2018-10-31

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

Phase 3 Completed

Neoplasm Metastasis, Neuroendocrine Tumors

NCT00227136 2018-04-13

Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion

Phase 3 Terminated

Carcinoid Tumor, Neuroendocrine Tumors

NCT01755182 2016-05-06

LOTUS

Phase 3 Terminated

Neuroendocrine Tumors

NCT01860742 2016-04-05

CASTOR

Phase 3 Withdrawn

Neuroendocrine Tumors